A phase I, open-label, dose-escalation trial of BI 1701963 as monotherapy and in combination with trametinib in patients with KRAS mutated advanced or metastatic solid tumors.

被引：0
|
作者：
Gort, Eelke
Johnson, Melissa Lynne
Hwang, Jimmy J.
Pant, Shubham
Dunzinger, Ulrich
Riemann, Kathrin
Kitzing, Thomas
Janne, Pasi A.
机构：
[1] Univ Med Ctr Utrecht, Utrecht, Netherlands
[2] Sarah Cannon Res Inst, Nashville, TN USA
[3] Levine Canc Inst, Charlotte, NC USA
[4] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[5] Boehringer Ingelheim Int GmbH, TA Oncol Med, Ingelheim, Germany
[6] Boehringer Ingelheim Pharma GmbH & Co KG, Global Clin Operat, Biberach, Germany
[7] Boehringer Ingelheim Pharma GmbH & Co KG, Translat Med & Clin Pharmacol, Biberach, Germany
[8] Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS3651
引用
收藏
页数：2
相关论文
共 50 条
  • [41] A phase 1, open-label, dose-escalation trial of oral TSR-011 in patients with advanced solid tumours and lymphomas
    Lin, Chia-Chi
    Arkenau, Hendrik-Tobias
    Lu, Sharon
    Sachdev, Jasgit
    de Castro Carpeno, Javier
    Mita, Monica
    Dziadziuszko, Rafal
    Su, Wu-Chou
    Bobilev, Dmitri
    Hughes, Lorraine
    Chan, Jian
    Zhang, Zhi-Yi
    Weiss, Glen J.
    BRITISH JOURNAL OF CANCER, 2019, 121 (02) : 131 - 138
  • [42] A phase 1, open-label, dose-escalation trial of oral TSR-011 in patients with advanced solid tumours and lymphomas
    Chia-Chi Lin
    Hendrik-Tobias Arkenau
    Sharon Lu
    Jasgit Sachdev
    Javier de Castro Carpeño
    Monica Mita
    Rafal Dziadziuszko
    Wu-Chou Su
    Dmitri Bobilev
    Lorraine Hughes
    Jian Chan
    Zhi-Yi Zhang
    Glen J. Weiss
    British Journal of Cancer, 2019, 121 : 131 - 138
  • [43] Phase I/II open-label, dose-escalation trial of rituximab (Rituxan®) in patients with SLE.
    Anolik, JH
    Campbell, D
    Ritchlin, C
    Holyst, M
    Rosenfeld, S
    Sanz, I
    Young, F
    Felgar, R
    Kunkel, L
    Benyunes, M
    Grillo-Lopéz, A
    Rosenblatt, J
    Looney, RJ
    ARTHRITIS AND RHEUMATISM, 2000, 43 (12): : 2860 - 2860
  • [44] A phase I, first-in-human, multicenter, open-label, dose-escalation study of IPH5201 as monotherapy or in combination with durvalumab ± oleclumab in advanced solid tumours
    Powderly, J.
    Bendell, J. C.
    Carneiro, B. A.
    Italiano, A.
    Macarulla Mercade, T.
    Castanon Alvarez, E.
    Imbimbo, M.
    Massard, C.
    Mueller, N.
    Gasco-Hernandez, A.
    ANNALS OF ONCOLOGY, 2020, 31 : S728 - S729
  • [45] Safety and efficacy of JS']JSKN003 in patients with advanced/metastatic solid tumors: A first-in-human, dose-escalation, multicenter, open-label, phase I study
    Park, John J.
    Gao, Bo
    Beecroft, Claire
    Wilkinson, Kate Jessica
    Parsonson, Andrew
    Zhang, Karl
    Yan, Xiangyun
    Wang, Ni
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [46] First-in-human, phase 1, open-label, dose-escalation, dose-expansion study of ADCT901 as monotherapy in patients with select advanced solid tumors
    Harvey, R. Donald
    Falchook, Gerald Steven
    Naqash, Abdul Rafeh
    Kim, Joseph W.
    Dowlati, Afshin
    Le Bruchec, Yvan
    Coudert, Isabelle
    Ervin-Haynes, Annette L.
    Sommerhalder, David
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [47] Safety and efficacy of JS']JSKN003 in patients with advanced/metastatic solid tumors: A first-in-human, dose-escalation, multicenter, open-label, phase I study
    Beecroft, Claire
    Gao, Bo
    Park, John
    Wilkinson, Kate
    Zhang, Karl
    Yan, Xiangyun
    Lv, Yuan
    CANCER RESEARCH, 2024, 84 (07)
  • [48] An open label phase I/Ila study to evaluate the safety and efficacy of CCS1477 as monotherapy and in combination in patients with advanced solid/metastatic tumors.
    De Bono, Johann S.
    Cojocaru, Elena
    Plummer, Elizabeth Ruth
    Knurowski, Tomasz
    Clegg, Karen
    Ashby, Fay
    Pegg, Neil
    West, William
    Brooks, Anthony Nigel
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [49] A phase I, open label, multicenter dose escalation study of AZD2811 nanoparticle in patients with advanced solid tumors.
    Johnson, Melissa Lynne
    Cosaert, Jan G. C. E.
    Falchook, Gerald Steven
    Jones, Suzanne Fields
    Strickland, Donald
    Greenlees, Carol
    Charlton, Julie
    MacDonald, Alexander
    Overend, Philip
    Adelman, Carrie
    Burris, Howard A.
    Pease, Elizabeth J.
    Patel, Gargi Surendra
    Wang, Judy Sing-Zan
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [50] A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY AND TOLERABILITY STUDY OF NC762 IN SUBJECTS WITH ADVANCED OR METASTATIC SOLID TUMORS
    Myint, Han
    Shah, Satish
    Gutierrez, Martin
    Zsiros, Emese
    Nelson, Megan
    Zeidan, Stephanie
    Myrthil, Nadia
    Morawski, Aaron
    Barbu, Alina
    Shaik, Jahangheer
    Zhou, Chelsea
    Kanellopoulou, Chrysi
    Copeland, Ron
    Cusumano, Zachary
    Flies, Dallas
    Langermann, Solomon
    Lorusso, Patricia
    Odunsi, Kunle
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A781 - A781
12345